More about

Atezolizumab

News
January 19, 2021
4 min read
Save

Atezolizumab-bevacizumab combination provides ‘longest survival seen’ in advanced HCC

Atezolizumab-bevacizumab combination provides ‘longest survival seen’ in advanced HCC

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.

News
January 13, 2021
2 min read
Save

Healio round-up: 2020 game changing lung cancer trials

2020 presented many challenges, including the transformation of conferences and meetings into virtual events.

News
January 05, 2021
1 min read
Save

FDA grants breakthrough therapy designation to tiragolumab, Tecentriq for NSCLC subset

FDA grants breakthrough therapy designation to tiragolumab, Tecentriq for NSCLC subset

The FDA granted breakthrough therapy designation to tiragolumab combined with atezolizumab for the first-line treatment of patients with metastatic non-small cell lung cancer.

News
October 27, 2020
9 min read
Save

Advances in treatments for genitourinary malignancies provide silver lining to 2020

Advances in treatments for genitourinary malignancies provide silver lining to 2020

This year has seen some groundbreaking advances in genitourinary oncology, particularly in the fields of prostate, kidney and urothelial cancers.

News
October 19, 2020
2 min read
Save

Overuse of antibiotics may shorten survival in urothelial carcinoma

Overuse of antibiotics may shorten survival in urothelial carcinoma

The overprescribing and overuse of antibiotics has been scrutinized in recent years due to the threat of antimicrobial resistance.

News
September 25, 2020
3 min read
Save

Neoadjuvant atezolizumab, chemotherapy improve outcomes in triple-negative breast cancer

Neoadjuvant atezolizumab, chemotherapy improve outcomes in triple-negative breast cancer

The addition of atezolizumab to neoadjuvant chemotherapy improved pathologic complete response rates regardless of PD-L1 expression in early triple-negative breast cancer, according to data presented at ESMO Virtual Congress 2020.

News
September 24, 2020
4 min read
Save

Atezolizumab regimen fails to extend PFS in triple-negative breast cancer subset

Atezolizumab regimen fails to extend PFS in triple-negative breast cancer subset

The addition of atezolizumab to paclitaxel failed to significantly prolong PFS for patients with PD-L1-positive metastatic triple-negative breast cancer, according to phase 3 study results presented during ESMO Virtual Congress 2020.

News
September 09, 2020
1 min read
Save

FDA issues alert about use of Tecentriq with paclitaxel for breast cancer

FDA issues alert about use of Tecentriq with paclitaxel for breast cancer

The FDA alerted health care professionals and oncology researchers that a trial of atezolizumab plus paclitaxel did not appear effective for the treatment of patients with advanced triple-negative breast cancer.

News
September 06, 2020
1 min read
Save

Eight important updates for National Prostate Cancer Awareness Month

Eight important updates for National Prostate Cancer Awareness Month

National Prostate Cancer Awareness Month is observed every September.

News
July 30, 2020
1 min read
Save

FDA approves Tecentriq plus Cotellic and Zelboraf for advanced melanoma

The FDA today approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600-positive advanced melanoma, according to a manufacturer-issued press release.

View more